Those included an mTOR inhibitor (AMPK agonist) and an EGFR inhibitor (gefitinib), two targets that have been previously reported to prevent oral cancer development in the 4-NQO model [26, 27]. Here, EGFR is linked to lip and oral cavity carcinoma.